Clinical Trial Update: Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a fourth-generation Immucillin derivative (DI4G) associated therapy in cutaneous leishmaniasis has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis
• Leishmaniasis

Drugs mentioned

• DI4G (DI4G)
• Immucillin derivative

Snippet

Sponsor: Hospital Universitário Professor Edgard Santos | Conditions: Leishmaniasis, Leishmaniasis, Cutaneous | Phase 2 | Status: COMPLETED